Evidence map›Paper›PMID 31758517›Full record

ArticleAdvances in therapy2020

Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.

Flávia B B Arantes, Fernando R Menezes, Andre Franci, Carlos J D G Barbosa, Talia F Dalçoquio, Carlos A K Nakashima, Luciano M Baracioli, Remo H M Furtado, Quintiliano S S Nomelini, José A F Ramires and 2 more

3 registry-linked trialsOpen access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02389582 phase4completednot on this map

Effects of LMWH Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease

TypeinterventionalSponsorUniversity of Sao Paulo General HospitalRan2014 to 2015Enrolled29ConditionsCoronary DiseaseArmsDabigatran, Enoxaparin
NCT05122455 phase2 / phase3completednot on this mapstarted 2021, after this paper: background citation

Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease

TypeinterventionalSponsorUniversity of Sao PauloRan2021 to 2024Enrolled61ConditionsSCAD, AMIArmsASA, Clopidogrel, Edoxaban
NCT05956145 nacompletednot on this mapstarted 2021, after this paper: background citation

Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease

TypeinterventionalSponsorUniversity of Sao PauloRan2021 to 2024Enrolled80ConditionsPlatelet Aggregation, Spontaneous, Coronary Artery DiseaseArmsColchicine 0.5 MG, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Ex Vivo Antiplatelet Effects of Oral Anticoagulants.Journal of cardiovascular development and disease · 2024
    Article
  3. Article
  4. Review
  5. Global Thrombosis Test: Occlusion Is Attributable to Shear-Induced Platelet Thrombus Formation.TH open : companion journal to thrombosis and haemostasis · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Flávia B B ArantesInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Fernando R MenezesInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Andre FranciInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Carlos J D G BarbosaInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Talia F DalçoquioInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Carlos A K NakashimaInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Luciano M BaracioliInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Remo H M FurtadoInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Quintiliano S S NomeliniFederal University of Uberlândia, Uberlândia, Brazil.
José A F RamiresInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Roberto Kalil FilhoInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
José C NicolauInstituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. corjnicolau@incor.usp.br.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRUniversidade Federal de Uberlândia · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe interaction between anticoagulants and platelet function is complex. Previous publications showed mixed results regarding the role of heparins in platelet aggregation. On the other hand, the direct thrombin inhibitor (DTI) dabigatran might enhance the risk of myocardial infarction in patients with atrial fibrillation, which could be related to increased platelet aggregability.

methodsThis was a prospective, interventional study of patients with chronic coronary artery disease (CAD) taking low-dose aspirin. The objective of the current study was to compare the effects of dabigatran versus enoxaparin on platelet aggregability. Subjects initially were on orally administered dabigatran for 5 days followed by subcutaneously administered enoxaparin after a 30-day washout period. Platelet function was assessed at baseline and after each intervention by multiple electrode aggregometry (MEA-ASPI) (primary endpoint), serum thromboxane B2 (TXB2), VerifyNow Aspirin™, and coagulation tests (secondary endpoints).

resultsCompared to baseline MEA-ASPI values, dabigatran increased platelet aggregation while enoxaparin decreased platelet aggregation (+ 5 U ± 24.1 vs - 6 U ± 22.2, respectively, p = 0.012). The TXB2 assay showed the same pattern (+ 2 pg/ml for dabigatran vs - 13 pg/ml for enoxaparin, p = 0.011). None of the additional tests showed significant differences between the groups. Individually, compared to baseline TXB2 results, enoxaparin significantly decreased platelet activation [33 (16.5-95) pg/mL vs 20 (10-52) pg/mL, respectively, p = 0.026], but no significant differences were observed with dabigatran.

conclusionsDTI and anti-Xa drugs exert opposite effects on platelet function. A significant decrease in platelet activation through COX1 (also known as prostaglandin G/H synthase 1) was observed with enoxaparin, but no significant differences in platelet function were observed with dabigatran.

trial registrationClinicalTrials.gov identifier, NCT02389582.

Indexed as

AgedAntithrombinsCoronary Artery DiseaseDabigatranEnoxaparinFemaleHeparin, Low-Molecular-WeightHumansMaleMiddle AgedPlatelet AggregationProspective StudiesAntithrombinsDabigatranEnoxaparinHeparin, Low-Molecular-WeightAnti-XaAspirinCoronary artery diseaseDirect thrombin inhibitorPlatelet aggregability

Identifiers

PMID31758517
PMCPMC6979460
OpenAlexW2990031521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.